The seminar focuses on US supply chain resiliency, while remaining compliant and preserving patient access.

A case study explores a way to potentially transform commercial organizations, while driving revenue growth.

The latest news for pharma industry insiders.

A panel uncovers how distribution channels are aligning commercialization efforts.

Conference keynote speech examines the industry’s critical developments of 2024 and offers a strategic outlook for next year.

The latest news for pharma industry insiders.

Because of the potential for product shortages at pharmacies, the FDA has not only given industry more time for compliance—but time to catch up on boosting the supply chain’s interoperable efforts.

A cohort study of cancer drugs analyzes where the priorities of pricing policies should lie.

Filling the gaps in the patient journey within an increasingly complex data environment.

In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Joe Lipari, director of product management, Systech, predicts the probability that these DSCSA compliance deadlines put forth by the FDA will be met.

The latest news for pharma industry insiders.

A guide to overcoming the top obstacles facing patient services programs today.

The importance of embracing universal values and business models that prioritize humanity.

The companies will be financially committing $1 and $3 billion into their respective manufacturing facilities.

In the third part of this roundtable discussion, experts discuss the value of Michigan State University’s Axia Institute—including its RFID testing efforts—and dive into the Institute’s end-to-end RFID pilot that it has been conducting.

Addressing the bottlenecks in cell and gene therapy manufacturing through a well-designed artificial intelligence approach is essential to avoiding data siloes.

The latest news for pharma industry insiders.

Is the potential of a more formal policy integration for health issues and disease prevention a scary suggestion or a good Idea?

While the program could be a good option for many, it's not a panacea.

A crash course on the bubble itself, including therapeutic areas most affected.

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Joe Lipari, director of product management, Systech, comments on what the repercussions are for failing to comply with the DSCSA.

The latest news for pharma industry insiders.

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Joe Lipari, director of product management, Systech, describes the latest state of DSCSA implementation guidelines.

A qualitative analysis consisting of patients, care partners, and oncology clinicians measures the sources of time burdens, along with how these impact various individuals.

The latest news for pharma industry insiders.